Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Medical Industry Today.
Press releases published on May 29, 2025
Beghou Consulting Adds New Partners to Strengthen Market Access, Cell & Gene Therapy, and Technology Capabilities
GlobeNewswire
·
May 29, 2025
EVANSTON, Ill., May 29, 2025 (GLOBE NEWSWIRE) -- Beghou Consulting, a leading provider of data, analytics, and technology solutions for life sciences commercialization, today announced that highly-regarded industry leaders Robert Rouse and Jason Stephani …
Cocrystal Pharma’s Investigational Drug Candidate CC-42344 Demonstrates Strong Antiviral Potency Against the 2024 Highly Pathogenic H5N1 Avian Influenza Strain
GlobeNewswire
·
May 29, 2025
CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain The Company’s virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the …
New study shows significant decline in men’s mental health; half lack sufficient social support
GlobeNewswire
·
May 29, 2025
Stress and depression risk increase for Canadian men One in two men lack sufficient social support networks Canadian Men’s Health Foundation launches #NeverAlone campaign for Men’s Health Month in June VANCOUVER, British Columbia, May 29, 2025 (GLOBE …
SweetWater Brewing and Zoo Atlanta Celebrate 18 Years of Collaboration with a Special Edition Beer
GlobeNewswire
·
May 29, 2025
ATLANTA, May 29, 2025 (GLOBE NEWSWIRE) -- SweetWater Brewing Company (“SweetWater Brewing” or “SweetWater”), the largest craft brewer in the Southeast and a Tilray Brands, Inc. company (NASDAQ: TLRY and TSX: TLRY) is thrilled to extend their partnership …
DiagnaMed Acquires Strategic Ontario Claims Adjacent to QIMC in Premier Temiscamingue Hydrogen District
GlobeNewswire
·
May 29, 2025
TORONTO, May 29, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a Canadian technology innovator specializing in advanced hydrogen extraction technologies, is pleased to announce the strategic …
Erasca to Present at Upcoming Investor Conferences in June
GlobeNewswire
·
May 29, 2025
SAN DIEGO, May 29, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today …
Safety Shot Reminds Shareholders to Vote Their Proxy at the Upcoming Annual Shareholder Meeting
GlobeNewswire
·
May 29, 2025
SCOTTSDALE, Ariz., May 29, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (“SHOT”, "Safety Shot”, or the “Company”), a wellness and dietary supplement company, reminds shareholders that its Annual Shareholders’ Meeting will be held on Thursday, …
Alzamend Neuro Announces Dosing of First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital
GlobeNewswire
·
May 29, 2025
Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 29, 2025 (GLOBE …
Digital Landia, LLC, in Cooperation with PetVivo Holdings, Inc., Announces Invite-Only MVP Availability Amid Stress-Testing & Debugging Phase
GlobeNewswire
·
May 29, 2025
MIAMI, FL, May 29, 2025 (GLOBE NEWSWIRE) -- Digital Landia, LLC (“Digital Landia”), owner of Agentic.Pet, an autonomous pet artificial intelligence ecosystem, in cooperation with PetVivo Holdings, Inc. (OTCQB: PETV; OTCPINK: PETVW) and its wholly owned …
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced the completion of patient …
Context Therapeutics to Appoint Dr. Karen Chagin, M.D. as Chief Medical Officer
GlobeNewswire
·
May 29, 2025
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced the appointment …
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with renal, metabolic and cardiovascular diseases, …
Apogee Therapeutics to Participate at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
SAN FRANCISCO and BOSTON, May 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025, at …
Vima Therapeutics Launches to Advance the First Oral Therapy for People with Dystonia and Related Movement Disorders
GlobeNewswire
·
May 29, 2025
- $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for …
Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance
GlobeNewswire
·
May 29, 2025
NEW YORK and MELBOURNE, Australia, May 29, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company developing novel combination therapies, today announced that the Phase 3 component of the RePOSA clinical …
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma, Inc. (“Crescent”), a private biotechnology company developing novel precision-engineered molecules targeting validated biology to advance care for patients with solid tumors, today …
uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
GlobeNewswire
·
May 29, 2025
~ No serious adverse events and 92% reduction in seizure frequency observed in the first trial participant through first five months of follow up ~ ~ Data to be presented today at Epilepsy Therapies …
Zenas BioPharma to Present at the Jefferies Global Healthcare Conference
GlobeNewswire
·
May 29, 2025
WALTHAM, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …
Syndax Announces Participation in June Investor Conferences
GlobeNewswire
·
May 29, 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, as well as …
Axsome Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
May 29, 2025
NEW YORK, May 29, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it will participate in three upcoming …